Four exhibits at Albany Museum of Art in final days

Bayer will create partnership between Ag Biologicals Powerhouse and Ginkgo Bioworks, which will advance Joyn Bio technology platforms

Northampton, MA – News Direct– Bayer

MONHEIM, Germany, April 25, 2022 / 3BL Media / – Bayer announced that the company is pursuing an agreement under which Ginkgo Bioworks will acquire Bayer’s West Sacramento Biologics (R&D) research and development (R&D) site and platform of internal discovery and lead optimization. The planned transaction, which is expected to conclude by the end of 2022 pending the final negotiation of the terms of the agreement and subject to regulatory approvals, would also bring Joyn Bio’s nitrogen fixing technologies to Bayer, successfully closing the joint venture. created between Leaps by Bayer and Ginkgo Bioworks in 2017. Ginkgo Bioworks will become a multi-year strategic microbial partner with Bayer in their work to develop biological solutions in fields such as nitrogen optimization, carbon sequestration and next generation crop protection .

The transaction will allow Bayer to expand its leading position in the organic sector, strengthen its access to key enabling technologies in synthetic biology and maintain Bayer’s role as the preferred research, development and commercial partner in the organic segment.

“Bayer’s work in the rapidly growing biological space is an essential part of our commitment to sustainability and delivering effective smart climate products such as nitrogen fixation and optimization technologies,” said Bob Reiter, head research and development of Bayer’s Crop Science division. “Our work with Ginkgo will accelerate our organic product pipeline by leveraging Bayer’s expertise in bringing reliable and effective organic products to market against Ginkgo’s synthetic biology search engine – now powered by an expanded R&D platform of organic products – and will help Bayer continue to expand our organic product range to create bespoke solutions for additional crops ”.

This strategic shift to an exclusively external biological research discovery pipeline with leading partners will activate the international ecosystem of open innovation and enable Bayer to better leverage its proven ability in commercializing organic products to create class-leading products that meet the growing need for smart and sustainable climate options that complement traditional chemicals.

“This is an exciting time for organic products and Bayer understands that the development of the next generation of organic products must be accelerated to help growers address the challenges of climate change and food security, as well as to meet sustainability needs.” said Benoit Hartmann, Senior Vice President and Head of Biologics, Crop Science Division. “Bayer’s leading organic products such as Serenade and BioRise 2 are already being used by growers around the world to reduce the use of products associated with higher greenhouse gas emissions and improve yields. We anticipate that the organic industry will continue to grow rapidly over the next decade and are ready to leverage our expertise, experience and resources to not only maintain but also expand our leadership position in the organic sector with a diverse set of leading partners. “

Joyn Bio’s R&D platform aims to join forces with Ginkgo Bioworks along with Bayer’s West Sacramento R&D platform through this transaction at closure expected later this year. Joyn’s successful developments in exploring the potential of synthetic biology in nitrogen fixation and other projects will be brought together under one roof with Bayer’s proven biological product development and optimization platform to strengthen discovery and development. of organic products and allow accelerated work on sustainable innovative technologies for agriculture.

“Ginkgo is an established and growing leader in synthetic biology and we are now bringing the success we have demonstrated in other complex and regulated industries to agriculture through the acquisition of the Bayer Biologics West Sacramento site along with its lead discovery and optimization platforms. , and continue to build on the work of our joint venture with Bayer, Joyn Bio, ”said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. “We want agricultural biological development to be as simple and efficient as computer programming, and by combining Ginkgo’s expertise in early organic discovery and development with Bayer and Joyn’s platforms, we will be able to offer effective pathways to the market for Bayer’s Biologics division “.

Bayer Biologicals offers growers benefits through reliable tailor-made solutions in both organic and conventional farming operations. In addition to pest management capabilities, organic solutions can be used to improve soil, root and plant health to provide greater yield and quality in many crops. The expanded range of choices available to organic growers provides complementary ways of managing pests and diseases alongside traditional chemicals, often increasing crop efficiency, making them a seamless integration into modern integrated farming management programs.

About BayerBayer is a global company with core competencies in the life sciences of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to address the major challenges presented by a growing and aging global population. Bayer is committed to promoting sustainable development and generating a positive impact with its activities. At the same time, the Group aims to increase its earning capacity and create value through innovation and growth. The Bayer brand is synonymous with trust, reliability and quality around the world. In fiscal year 2021, the Group employed approximately 100,000 people and recorded sales of € 44.1 billion. Research and development expenses before special items amounted to € 5.3 billion. For more information, visit

About GinkgoGinkgo is building a platform to allow customers to program cells as easily as we can program computers. The company’s platform enables biotechnology applications in diverse markets, from food to agriculture, industrial chemistry to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including combined K-12 testing, optimization of vaccine manufacturing, and discovery of therapies. For more information, visit

About Joyn BioJoyn Bio is bringing synthetic biology to agriculture for better ways to feed the world. A joint venture between Leaps by Bayer and Ginkgo Bioworks, Joyn designs microbes to enhance natural processes such as nitrogen fixation, offering growers more reliable solutions for crop protection and nutrition and reducing environmental impact. Joyn Bio brings together leading scientists with diverse backgrounds at its two sites in Boston, Massachusetts and Woodland, California. For more information, visit

More information at

Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer’s management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates provided herein. These factors include those discussed in Bayer’s public reports, available on Bayer’s website at The company assumes no responsibility for updating these forward-looking statements or for conforming them to future events or developments.

View additional media and other ESG narratives from Bayer at

View source version on

Leave a Comment

Your email address will not be published.